{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.5","upperLimit":"73.2","value":"68.4"},{"groupId":"OG001","lowerLimit":"55.5","upperLimit":"65.8","value":"60.7"},{"groupId":"OG002","lowerLimit":"63.8","upperLimit":"73.6","value":"68.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"346"},{"groupId":"OG002","value":"342"}],"units":"Participants"}],"description":"PSA response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value ≥10 ng/mL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Docetaxel (TXT) 75 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG000","title":"Docetaxel 75 mg/m^2"},{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG001","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG002","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on ITT population. Number of participants analyzed=participants with PSA value ≥10 ng/mL at baseline and at least one valid post-baseline value for specified outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)","title":"Percentage of Participants With PSA Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}